End-stage renal disease: A state of chronic inflammation and hyperleptinemia [2]

European Journal of Clinical Investigation

Volumn 33, Issue 6, 2003, Pages 527-528

  Pecoits Filho, R ^a   Lindholm, B ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; HYALURONIC ACID; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CORRELATION ANALYSIS; DIALYSIS; HYPERLEPTINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; MALNUTRITION; METABOLIC DISORDER; MORTALITY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT OUTCOME;

EID: 0037561481     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01175.x     Document Type: Letter

References (15)

1. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19 (1):53-61.
2. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G et al. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 2002;62:1791-8.
3. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
4. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B et al. Associations between circulating inflammatory markers and residual renal function in ESRD patients. Am J Kidney Dis 2003, in press.
5. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002;39:274-82.
6. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998;31:93-100.
7. Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transpl 2002;17:1684-8.
8. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002;62:949-55.
9. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leucocyte recruitment seen during acute inflammation. Immunity 2001;14:705-14.
10. Heimbürger O, Wang T, Lönnqvist F, Stenvinkel P. Peritoneal clearance of leptin in CAPD patients: impact of local insulin administration. Nephrol Dial Transplant 1999;14 (3):723-7.
11. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumour necrosis factor-α contributes to obesity-related hyperleptinameia by regulating leptin release from adipocytes. J Clin Invest 1997;100:2777-82.
12. Stenvinkel P, Lönnqvist F, Schalling M. Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant 1999;14 (5):1103-12.
13. Pecoits-Filho RFS, Nordfors L, Heimbürger O, Lindholm B, Anderstam B, Marchlewska A et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest 2002;32:811-7.
14. Don BR, Rosales LM, Leyine NW, Mitch W, Kaysen GA. Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 2001;59:1114-20.
15. Singhal A, Farooqi S, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M et al. Influence of leptin on arterial distensibility. A novel link between obesity and cardiovascular disease. Circulation 2002;106:1919-24.